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Focused cardiac ultrasound screening for rheumatic heart 
disease by brieﬂ y trained health workers: a study of 
diagnostic accuracy
Daniel Engelman, Joseph H Kado, Bo Reményi, Samantha M Colquhoun, Jonathan R Carapetis, Susan Donath, Nigel J Wilson, Andrew C Steer
Summary
Background Echocardiographic screening for rheumatic heart disease (RHD) can identify individuals with subclinical 
disease who could beneﬁ t from antibiotic prophylaxis. However, most settings have inadequate resources to 
implement conventional echocardiography and require a feasible, accurate screening method. We aimed to investigate 
the accuracy of screening by non-expert operators using focused cardiac ultrasound (FoCUS).
Methods In this prospective study of diagnostic accuracy, we recruited schoolchildren aged 5 to 15 years in Fiji to 
undergo two blinded tests. The index test was a FoCUS assessment of mitral and aortic regurgitation, performed by 
nurses after an 8-week training programme. The reference standard was the diagnosis of RHD by a paediatric 
cardiologist, based on a standard echocardiogram performed by a skilled echocardiographer. The primary outcome 
was the accuracy of the index test with use of the most sensitive criteria (any regurgitation).
Findings We included 2004 children in the study. The index tests were done between September, 2012, and 
September, 2013, by seven nurses in eight schools in Fiji. The diagnostic accuracy of the screening test (area under 
receiver operator characteristic curve) was 0·89 (95% CI 0·83–0·94). When the primary cut-oﬀ  point (any 
regurgitation) was used for analysis, sensitivity was 84·2% (72·1–92·5) and speciﬁ city was 85·6% (83·9–87·1). The 
sensitivity of individual nurses ranged from 66·7% to 100% and speciﬁ city 74·0% to 93·7%.
Interpretation Screening by brieﬂ y trained nurses using FoCUS was accurate for the diagnosis of RHD. Reﬁ nements 
to training and screening test methods should be studied in a range of settings, and in parallel with investigations of 
the long-term clinical and cost-eﬀ ectiveness of screening for RHD.
Funding Cure Kids, New Zealand; the Fiji Water Foundation provided funding for portable ultrasound equipment; 
see acknowledgments for further details of funders.
Copyright © Engelman et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Rheumatic heart disease (RHD) is an important cause of 
global morbidity and mortality.1 Patients typically present 
late in the illness, and there is a high risk of death in the 
ﬁ rst years after diagnosis.2,3 Screening can detect people 
who might beneﬁ t from secondary antibiotic prophylaxis, 
and is recommended by WHO in high-prevalence areas;4 
however, there is a lack of evidence to inform imple-
mentation. 5,6
Population screening requires a test that is safe, accurate, 
and readily available.7 Echocardiography is safe and much 
more accurate for diagnosing RHD than is clinical 
evaluation.8–10 However, the shortage of echocardiographers 
and cardiologists to perform and interpret echocardiograms 
is a major barrier to their use and hampers scale-up of 
screening to the population level.11 Task shifting screening 
to non-expert health workers could overcome the human 
resource con straints.12,13 In this approach, nurses who have 
completed a short training course use focused cardiac 
ultrasound (FoCUS) to screen for valvular regurgitation, 
and refer positive cases for diagnostic assessment, 
including standard echocardiography.
In Fiji, there are too few physicians to perform 
echocardiographic screening, but the country does have a 
capable nursing workforce and a nurse-led school health 
programme. Therefore, we sought to assess whether task 
shifting FoCUS to existing school-health nurses is a 
feasible strategy for implementation of population 
screening for RHD. We have shown in a pilot study14 that 
the training of nurses in ultrasound-based RHD 
screening was feasible. We have also reported in another 
study,15 that nurses who had undertaken an 8-week 
training course could acquire FoCUS images of 
appropriate quality and accurately measure regurgitation. 
Here, we aimed to investigate the accuracy of FoCUS 
screening tests done by non-experts, using a range of cut-
oﬀ  criteria.
Methods
Study design and setting
In this prospective investigation of the accuracy of a new 
test,16 the index test was FoCUS for RHD, performed by 
nurses who had completed a deﬁ ned training 
programme, using a simpliﬁ ed protocol and portable 
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ultrasound machines. The reference standard was the 
diagnosis of RHD by a paediatric cardiologist, based on 
ﬁ ndings from a standard echocardiogram. This study 
took place in Fiji, a South Paciﬁ c nation with a population 
of about 900 000 people and a high prevalence of RHD.10
The study was approved by the Fiji National Health 
Research Committee and Menzies School of Health 
Research, Australia.
Procedures
In June and July, 2012, school-health nurses in Fiji, who 
had only a basic understanding of cardiac anatomy and 
physiology and no previous imaging experience, were 
trained to screen for RHD using FoCUS. Training 
included 1 week of classroom-based workshops and 
7 weeks of practical training, as reported elsewhere.17
The evaluation of the screening test was conducted in 
eight primary schools in the Central, Northern, and 
Western administrative divisions of Fiji (ﬁ gure 1). Children 
underwent two tests: a FoCUS performed by a nurse, and 
a standard echocardiogram by an echocardiographer. Tests 
were done in diﬀ erent rooms, so that the nurse and 
echocardiographer were not aware of the other’s ﬁ ndings. 
We aimed to have both tests take place on the same day.
Nurses followed a simpliﬁ ed 12-step protocol, assessing 
the presence of mitral regurgitation or aortic regurgitation 
on colour Doppler imaging in the parasternal long axis, 
parasternal short axis, and apical views, and if present, 
measuring the longest visible jet (appendix). To attempt 
to avoid the measurement of benign closing volumes, we 
asked nurses to measure regurgitation only if it had been 
seen in two or more frames. Nurses made assessments 
at the time of examination and clinical information was 
not available to them. All images and loops were saved. 
Nurses used the M-Turbo portable ultrasound machine 
(SonoSite Inc, Bothell, WA, USA), chosen for acceptable 
colour Doppler imaging and relative aﬀ ordability, 
therefore representing the type of machine that could be 
practical to procure and use in resource-limited and 
remote settings.
The echocardiographer was highly skilled in RHD 
imaging, and performed a directed echocardiogram, 
including parasternal long axis, parasternal short axis, 
and apical views on all children, and continued to an 
extended echocardiogram, including continuous-wave 
Doppler and M-mode imaging if any of the following 
abnormalities were seen: mitral regurgitation ≥1·5cm; 
aortic regurgitation ≥0·5 cm; mitral or aortic stenosis; 
morphological features of RHD as described in the 
2012 World Heart Federation (WHF) criteria;18 or any 
other pathology. The echocardiographer used a Vivid 
e ultrasound machine (GE Healthcare, Freiburg, 
Germany), which has been used in other screening 
studies.19,20
Standard echocardiograms were reported by a 
paediatric cardiologist, who was unaware of the nurses’ 
assessment or any clinical information. Diagnosis was in 
accordance with WHF criteria,18 with categories of 
normal, borderline RHD, deﬁ nite RHD, and congenital 
abnormalities. The severity of RHD was based on a 
grading of valvular regurgitation and/or stenosis.21,22 If 
there was diagnostic uncertainty, a second cardiologist 
reported the echocardiogram. In the case of an 
inconsistent diagnosis between the ﬁ rst and second 
cardiologist, the report of a third cardiologist was used. 
We entered data into a REDCap electronic database 
hosted at the Murdoch Childrens Research Institute 
in Melbourne, Australia.23 Children with abnormal 
echocardiograms were referred to specialist centres for 
diagnostic assessment and management.
Participants
Seven nurses participated: two from each of the three 
administrative Divisions and one additional nurse from 
Central Division in case of dropout. We included schools 
that would allow each nurse to screen within their local 
Division and do approximately equal numbers of tests 
(ﬁ gure 1). Research staﬀ  explained study procedures to 
students, parents, and teachers at the participating 
schools and we provided information sheets in Fijian and 
 Research in context
Evidence before this study
A search of PubMed and Embase between Jan 1, 1990, and 
Dec 31, 2011, using search terms “non-expert”, “nurse”, 
“community health worker”, “education”, “echocardiography”, 
“ultrasound”, and “rheumatic heart disease”, and discussion 
with colleagues yielded no relevant publications. We repeated 
the search in December, 2015. We found two studies: both 
trained and assessed two nurses who used hand-held 
ultrasound for screening. Three additional feasibility studies 
were found.
Added value of this study
This study is large and is consistent with guidelines for studies of 
diagnostic accuracy. The design included training a large group of 
health workers and unsupervised screening at eight sites over 
12 months, which may be more representative of a real-world 
scenario than other studies. The training programme and test 
protocols were highly deﬁ ned and could be replicated in other 
settings. Our results show that the screening test was accurate. 
Additionally, these data clarify the inﬂ uence of various criteria and 
cut-oﬀ  points on test sensitivity and speciﬁ city. Our results also 
highlight the issue of variation in accuracy between operators.
Implications of all available evidence
Screening by non-expert operators, using simpliﬁ ed imaging 
protocols, has been shown to be accurate across all studies. 
Further studies and reﬁ nements of test methods should be 
explored.
See Online for appendix
Articles
www.thelancet.com/lancetgh   Vol 4   June 2016 e388
English. All children aged from 5 to 15 years who attended 
the selected schools were eligible to participate. Parents 
gave written consent for their children to participate, and 
we obtained assent from children aged 10 years or older. 
Participating nurses gave written informed consent.
Statistical analysis
 The primary analysis was the accuracy of the index test 
for the diagnosis of any RHD (including deﬁ nite and 
borderline disease). We also calculated test accuracy for 
deﬁ nite RHD. We used the area under the receiver 
operator characteristic curve (AUC ROC) for the longest 
mitral or aortic regurgitation jet measured in any view to 
calculate overall diagnostic accuracy.
The evaluation of criteria for screen-positivity compared 
the accuracy of the index test at diﬀ erent clinically relevant 
jet length cut-oﬀ  points. The primary analysis used cut-
oﬀ  points from the ROC curve for the longest mitral or 
aortic regurgitation jet in any view. Other exploratory 
combinations of criteria for screen positivity were then 
compared, including the longest mitral regurgitation 
measurement (excluding aortic regurgitation measure-
ments); adding any aortic regurgitation (>0 cm) to the 
longest mitral regurgitation; using diﬀ erent cut-oﬀ  points 
for mitral and aortic regurgitation (at 50%, 75%, and 
100% of the WHF criteria for pathological regurgitation); 
and adding the requirement for mitral regurgitation to be 
seen in more than one echocardiographic view. Accuracy 
was measured by sensitivity, speciﬁ city, predictive values, 
and diagnostic OR with 95% conﬁ dence intervals. Where 
the OR was not deﬁ ned because of a zero count, we 
calculated an approximate OR.24 We also recorded the 
accuracy of individual participating nurses. We used Stata 
version 13 (Statacorp LP, College Station TX, USA) for 
data analysis.
We calculated the sample size needed from formulae 
for diagnostic tests25 and used the assumption that 4% of 
children would have regurgitation jets in a clinically 
signiﬁ cant range.10 Based on results from our pilot 
study,14 a sensitivity of 95%, speciﬁ city of 75% and ±5% 
width of the conﬁ dence intervals, we calculated that a 
sample size of 1824 would be required and, therefore, we 
aimed to recruit 2000 children.
Role of the funding source
The funders had no role in study design; data collection, 
analysis, interpretation; or writing the report. The 
corresponding author had full access to all the data in the 
study and ﬁ nal responsibility for the decision to submit 
for publication.
Figure 1: Study sites in Fiji
Each pin represents one school screening site.
Eastern division
Northern division
0
0
25 50 miles
100 km755025
Western division
Central division
Eastern division
Labasa
Suva
Lautoka
Rotuma
Vanua Levu
Viti  Levu
N
Articles
e389 www.thelancet.com/lancetgh   Vol 4   June 2016
Results
Between Sept 11, 2012, and Sept 12, 2013, we recruited 
2023 children from eight schools in Fiji. We excluded 
children who had only had one test or if their reference 
echocardiogram was not interpretable, resulting in a ﬁ nal 
cohort of 2004 children included in analysis (ﬁ gure 2).
Of the investigations for included children, ﬁ ve were 
reviewed by a second reporter and three were referred to a 
third reporter. There were no missing data. Nurses assessed 
between 236 and 339 children each. Because of the 
unavailability of the echocardiographer, only 66% of paired 
tests were done on the same day and 94% within 28 days. A 
sensitivity analysis of participants with tests on the same 
day showed that testing on diﬀ erent days did not 
signiﬁ cantly aﬀ ect reported results (data not shown). There 
were no adverse events.
Mean age of enrolled children was 10·0 years 
(range 5·1–15·7, table 1). 51·4% were girls and 60·7% 
were iTaukei (indigenous Fijian). On the cardiologist’s 
report of the echocardiographer studies, 501 (25%) 
participants had regurgitation, 433 (21·6%) had mitral 
regurgitation, 41 (2·0%) had aortic regurgitation, and 
27 (1·3%) had both). There were 57 cases of RHD, with 
an overall prevalence of 28·4 per 1000 children (95% CI 
Figure 2: Study ﬂ ow diagram
FoCUS=focused cardiac ultrasound.
2023 eligible children
334 had regurgitation
329 had reference standard
 Diagnostic 
 Echocardiogram
1684 had no regurgitation
12 had definite RHD
36 had borderline RHD
281 had no RHD 2 had definite RHD
7 had borderline RHD
1666 had no RHD
2 did not have reference 
 standard test
3 had a reference standard 
 that was not interpretable
1675 had reference standard 
 Diagnostic 
 Echocardiogram
7 did not have reference 
 standard test
2 had a reference standard 
 that was not interpretable
2018 had index test
 FoCUS Assessment
5 did not have index test
 Whole cohort 
(n=2004)
Children with 
deﬁ nite RHD
Prevalence per 
1000 (95% CI)
Children with 
borderline 
RHD
Prevalence per 
1000 (95% CI)
Sex
Female 1031 (51·4%) 10 (71·4%) 9·7 (5·2–17·9) 31 (72·1%) 30·1 (21·2–42·4)
Male 973 (48·6%) 4 (28·6%) 4·1 (1·5–10·9) 12 (27·9%) 12·3 (7·0–21·6)
Age (years)
5–9 958 (47·8%) 4 (28·6%) 4·2 (1·6–11·1) 17 (39·5%) 17·7 (11·1–28·4)
10–15 1046 (52·2%) 10 (71·4%) 9·5 (5·1–17·7) 26 (60·5%) 24·8 (16·9–36·3)
Ethnicity
iTaukei 1217 (60·7%) 9 (64·3%) 7·4 (3·8–14·2) 35 (81·4%) 28·7 (20·7–39·8)
Fijian of Indian 
descent
736 (36·7%) 4 (28·6%) 5·4 (2·0–1·) 7 (16·3%) 9·5 (4·5–19·8)
Other 51 (2·5%) 1 (7·1%) 19·6 (2·6–128·7) 1 (2·3%) 19·6 (2·6–128·7)
Division
Northern 512 (25·5%) 2 (14·3%) 3·9 (0·9–15·5) 12 (27·9%) 23·4 (13·3–40·8)
Western 677 (33·8%) 4 (28·6%) 5·9 (2·2–15·6) 6 (14·0%) 8·9 (4·0–19·6)
Central 815 (40·7%) 8 (57·1%) 9·8 (4·9–19·5) 25 (58·1%) 30·7 (20·8–45·0)
Total 2004 14 7·0 (4·1–11·8) 43 21·4 (15·9–28·8)
RHD=rheumatic heart disease.
Table 1: Participant characteristics and prevalence of rheumatic heart disease
 Number of children 
with diagnosis
(%)
Deﬁ nite RHD 14 (0·7%)
A: Pathological MR with 
morphological features of MV
11
B: Mitral stenosis 1
C: Pathological AR with 
morphological features of AV
2
D: Borderline disease of AV and MV 0
Borderline RHD 43 (2·1%)
A: Morphological features of MV 16
B: Pathological MR 23
C: Pathological AR 4
Congenital abnormality 26 (1·3%)
Bicuspid AV 9
Congenital MV prolapse 6
Other* 11
Normal 1921 (95·9)
Total 2004 (100·0)
AR=aortic regurgitation. AV=aortic valve. MR=mitral regurgitation. MV=mitral 
valve. RHD=rheumatic heart disease.*Other congenital lesions were: coronary 
artery to pulmonary artery ﬁ stula (two children); atrial septal defect, patent 
ductus arteriosus, dilated left ventricle (unknown aetiology), dilated ascending 
aorta, dilated coronary sinus, dilated aortic sinus, accessory chordal tissue, 
subaortic membrane, septal hypertrophy (one child for each congenital 
abnormality).
Table 2: Cardiologist diagnosis from reference standard echocardiogram
Standard echocardiogram Total
Any RHD No RHD
FoCUS
Test positive 48 281 329
Test negative 9 1666 1657
Total 57 1947 2004
Positive test cut-oﬀ  point: any regurgitation (>0 cm) of either mitral or aortic 
valve. FoCUS=focused cardiac ultrasound. Any RHD=deﬁ nite or borderline 
rheumatic heart disease.
Table 3: Accuracy of nurse-performed FoCUS for screening of RHD 
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22·0–36·7), including 14 cases of deﬁ nite RHD 
(7·0 per 1000 children) and 43 cases of borderline RHD 
(21·4 per 1000 children, table 1). Six cases (10·5%) were 
isolated to the aortic valve (table 2). Of deﬁ nite RHD 
cases, two (14·3%) were severe, six (42·9%) were 
moderate, and six (42·9%) were mild. There were 
26 congenital cases (prevalence 12·9 per 1000 children); 
all were mild or clinically insigniﬁ cant (table 2).
The nurse operators reported 329 participants (16·4%) 
with regurgitation (306 [15·3%] with mitral regurgitation, 
26 [1·3%] with aortic regurgitation, and three [0·1%] with 
both). Regurgitation was not identiﬁ ed by nurses in nine 
of the 57 RHD cases reported by cardiologists (ie, false 
negatives). Conversely, nurses identiﬁ ed 281 cases of 
regurgitation that were not diagnosed as RHD by 
cardiologists (table 3). The diagnostic accuracy of the 
index test (AUC ROC, plotting the longest mitral or 
aortic regurgitation jet, appendix) was 0·89 (95% CI 
0·83–0·94). Maximum sensitivity at the primary cut-oﬀ  
point (mitral or aortic regurgitation >0 cm) was 84·2% 
Any RHD (n=57) Deﬁ nite RHD (n=14)
n Sensitivity Speciﬁ city PPV NPV Diagnostic OR n Sensitivity Speciﬁ city
Longest regurgitation jet (cm) 
MR or AR (primary 
analysis)
MR ≥0·5 or AR 
≥0·5
48 84·2 
(72·1–92·5)
85·6 
(83·9–87·1)
14·6 
(11·0–18·9)
99·5 
(99·0–99·8)
31·8 
(15·6–64·2)
12 85·7 
(57·2–98·2)
84·1 
(82·4–85·7)
MR ≥1 or AR ≥1 47 82·5 
(70·1–91·3)
87·4 
(85·6–88·8)
16·0 
(12·0–20·8)
99·4 
(98·9–99·7)
32·5 
(16·4–64·3)
12 85·7 
(57·2–98·2)
85·9 
(84·3–87·4)
MR ≥1·5 or AR ≥1·5 44 77·2 
(64·2–87·3)
93·8 
(92·6–94·8)
26·7 
(20·1–34·1)
99·3 
(98·8–99·6)
51·1 
(27·0–96·5)
12 85·7 
(57·2–98·2)
92·3 
(91·1–93·4)
MR ≥ or AR ≥2 28 49·1 
(35·6–62·7)
97·8 
(97·1–98·4)
40·0 
(28·5–52·4)
98·5 
(97·9–99·0)
43·8 
(24·1–79·7)
11 78·6 
(49·2–95·3)
97·0 
(96·2–97·7)
MR only
MR >0 46 80·7 
(68·1–90·0)
86·6 
(85·1–88·1)
15·0 
(11·2–19·5)
99·4 
(98·8–99·7)
27·1 
(14·0–52·5)
12 85·7 
(57·2–98·2)
85·2 
(83·6–86·8)
MR ≥1 45 78·9 
(66·1–88·6)
88·2 
(86·7–89·6)
16·4 
(12·2–21·3)
99·3 
(98·8–99·6)
28·0 
(14·7–53·2)
12 85·7 
(57·2–98·2)
86·8 
(85·2–88·2)
MR ≥1·5 42 73·7 
(60·3–84·5)
94·4 
(93·3–95·4)
27·8 
(20·8–35·7)
99·2 
(98·7–99·5)
47·2 
(25·6–87·1)
12 85·7 
(57·2–98·2)
93·0 
(91·8–94·1)
MR ≥2 26 45·6 
(32·4–59·3)
98·2 
(97·4–98·7)
41·9 
(29·5–55·2)
98·4 
(97·7–98·9)
44·5 
(24·1–82·2)
11 78·6 
(49·2–95·3)
97·4 
(96·6–98·1)
MR or any AR
MR >0 or AR >0 48 84·2 
(72·1–92·5)
85·6 
(83·9–87·1)
14·6 
(11·0–18·9)
99·5 
(99·0–99·8)
31·6 
(15·6–64·2)
12 85·7 
(57·2–98·2)
84·1 
(82·4–85·7)
MR ≥1 or AR >0 47 82·5 
(70·1–91·3)
87·1 
(85·5–88·6)
15·8 
(11·8–20·4)
99·4 
(98·9–99·7)
31·8 
(16·0–62·9)
12 85·7 
(57·2–98·2)
85·6 
(84·0–87·1)
MR ≥1·5 or AR >0 44 77·2 
(64·2–87·3)
93·3 
(92·1–94·3)
25·1 
(18·9–32·2)
99·3 
(98·8–99·6)
46·9 
(24·9–88·5)
12 85·7 
(57·2–98·2)
91·8 
(90·5–93·0)
MR ≥2 or AR >0 29 50·9 
(37·3–64·4)
97·0 
(96·2–97·7)
33·3 
(23·6–44·3)
98·5 
(97·9–99·0)
33·7 
(18·9–60·1)
11 78·6 
(49·2–95·3)
96·2 
(95·2–97·0)
Diﬀ erent cut–oﬀ 
MR ≥1 or AR≥0·5 47 82·5 
(70·1–91·3)
87·1 
(85·5–88·6)
15·8 
(11·8–20·4)
99·4 
(98·9–99·7)
31·8 
(16·0–62·9)
12 85·7 
(57·2–98·2)
85·6 
(84·0–87·1)
MR ≥1·5 or 
AR ≥0·75
44 77·2 
(64·2–87·3)
93·4 
(92·2–94·4)
25·4 
(19·1–32·6)
99·3 
(98·8–99·6)
47·7 
(25·3–90·0)
12 85·7 
(57·2–98·2)
91·9 
(90·6–93·1)
MR ≥2 or AR ≥1 29 50·9 
(37·3–64·4)
97·3 
(96·5–98·0)
35·4 
(25·1–46·7)
98·5 
(97·9–99·0)
37·0 
(20·7–66·3)
11 78·6 
(49·2–95·3)
96·4 
(95·5–97·2)
Jet length (cm) and multiple views
MR >0, 2 views or 
AR>0
46 80·7 
(68·1–90·0)
89·5 
(88·1–90·8)
18·4 
(13·8–23·8)
99·4 
(98·9–99·7)
35·7 
(18·4–69·3)
12 85·7 
(57·2–98·2)
88·0 
(86·5–89·4)
MR ≥1, 2 views or 
AR>0
45 78·9 
(66·1–88·6)
90·2 
(88·8–91·5)
19·1 
(14·3–24·7)
99·3 
(98·8–99·6)
34·5 
(18·1–65·6)
12 85·7 
(57·2–98·2)
88·7 
(87·3–90·1)
MR ≥1·5, 2 views or 
AR>0
44 77·2 
(64·2–87·3)
93·9 
(92·8–95·0)
27·2 
(20·5–34·7)
99·3 
(98·8–99·6)
52·5 
(27·7–99·2)
12 85·7 
(57·2–98·2)
92·5 
(91·2–93·6)
n=number of cases detected using screening criteria. PPV=positive predictive value. NPV=negative predictive value. Any RHD=deﬁ nite or borderline rheumatic heart disease. 
MR=mitral regurgitation. AR=aortic regurgitation.
Table 4: Accuracy of screening test criteria 
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(95% CI 72·1–92·5), which corresponded to a speciﬁ city 
of 85·6% (83·9–87·1). Sensitivity and speciﬁ city for 
deﬁ nite RHD were 85·7% and 84·1%, respectively. The 
sensitivity of criteria was increased by incorporating 
aortic regurgitation measurements, whereas speciﬁ city 
was increased by increasing regurgitation cut-oﬀ  lengths 
and by requiring mitral regurgitation to be seen in 
multiple views (table 4).
Of the seven nurses, one had a much lower accuracy 
than the others, with six of the nine false negatives 
screened by this operator, whereas other nurses had 
either one or none. When the primary cut-oﬀ  point 
(mitral or aortic regurgitation >0 cm) was used for 
analysis, the sensitivity of individual nurses ranged from 
66·7% to 100% and speciﬁ city 74·0% to 93·7% (table 5). 
As the least accurate nurse may have skewed the 
evaluation of the optimum criteria, we repeated analyses 
with this nurse excluded. In this scenario, sensitivity and 
speciﬁ city were 92·3% and 85·6%, respectively, for any 
regurgitation (appendix), and the AUC ROC was 0·93 
(appendix).
Discussion
Our study showed that a FoCUS screening test 
performed by nurses who had completed a brief, 
structured training programme was accurate for the 
diagnosis of RHD. The sensitivity and specify of the test 
were high. Although sensitivity (84% at the primary cut-
oﬀ  point) was below the 95% estimate used to calculate 
sample size, this level of accuracy might be acceptable 
for screening in some contexts. Reﬁ nements to training 
and screening test procedures could lead to further 
improvements in accuracy.
Analysis of individual nurses’ performances showed 
variation in accuracy, with the lowest sensitivity (67%) 
and speciﬁ city (74%) being below the desired standards. 
Two nurse operators were extremely accurate, screening 
with a sensitivity of 100% and speciﬁ city >90%. We noted 
similar variation in the quality of images and 
measurement of regurgitation by the seven nurses.15 
Although some variation between operators is to be 
expected, these data suggest that training protocols 
require further reﬁ nement. Speciﬁ cally, future training 
should require operators to demonstrate competency 
before they begin screening. In this study, we deliberately 
excluded such “hurdle” assessments or ongoing training, 
so that we could evaluate a highly-deﬁ ned programme. 
By contrast, a real-world screening programme would 
require quality assurance protocols, continued 
professional development, and supervision.7 We can 
hypothesise that, through training reﬁ nements, quality 
assurance and the beneﬁ ts of experience, programmatic 
test accuracy may approach or even exceed the level of 
accuracy of the best performing individual operators 
reported in this study.
The results of test accuracy using diﬀ erent criteria and 
cut-oﬀ  points do not conclusively identify the best 
strategy, but factors that contribute to accuracy are 
evident. Mitral regurgitation length is the main 
determinant of the accuracy of the test, whereas the 
aortic regurgitation cut-oﬀ  point has only a small eﬀ ect. 
Our results suggest the optimum mitral regurgitation jet 
length would be around 1–1·5 cm. Sensitivity reduces 
slightly at 1·5 cm (although the highest diagnostic OR is 
observed at this cut-oﬀ , because of increased speciﬁ city) 
and is unacceptably low at a cut-oﬀ  point of 2 cm. The 
referral of all patients with mitral regurgitation >0 cm 
would be most sensitive. Although the requirement for 
mitral regurgitation to be seen in two views improved the 
speciﬁ city of the test, it had the undesirable eﬀ ect of a 
loss of sensitivity.
We noted that 10% of participants with RHD had isolated 
aortic pathology, reinforcing our view that screening 
should include assessment for aortic regurgitation. Use of 
a diﬀ erent cut-oﬀ  point for mitral and aortic regurgitation 
appears preferable. Since aortic regurgitation far less 
Participants screened (n) Prevalence 
of any RHD 
(per 1000)
Accuracy
TP FP FN TN Total Sensitivity Speciﬁ city PPV NPV DOR
1 4 21 0 313 338 11·8 100·0 93·7 16·0 100·0 129*
2 6 33 0 300 339 17·6 100·0 90·1 15·4 100·0 117*
3 7 27 1 228 263 30·4 87·5 89·4 20·6 99·6 59·1
4 8 78 0 222 308 26·0 100·0 74·0 9·3 100·0 48·2*
5 5 34 1 209 249 24·1 83·3 86·0 12·8 99·5 30·7
6 6 51 1 178 236 29·7 85·7 77·7 10·5 99·4 20·9
7 12 37 6 216 271 66·4 66·7 85·4 24·5 97·3 11·7
Total 48 281 9 1666 2004 28·4 84·2 85·6 14·6 99·5 31·6
Positive test cut-oﬀ  point: any regurgitation (>0 cm) of either mitral or aortic valve. Any RHD=deﬁ nite or borderline rheumatic heart disease. TP=true positive. FP=false 
positive. FN=false negative. TN=true negative. PPV=positive predictive value. NPV=negative predictive value. DOR=diagnostic odds ratio. *DOR could not be calculated 
because of zero values, therefore approximated DOR shown.
Table 5: Accuracy of screening for rheumatic heart disease by individual nurses
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commonly represents normal echocardiographic variation, 
and that there were very few cases of aortic regurgitation 
<1 cm, suggests that the best approach might be to refer all 
children who have any degree of aortic regurgitation.
Three other studies have considered criteria for an 
abbreviated RHD screening test. Ploutz and colleagues26 
noted that a combination of mitral regurgitation ≥1·5 cm 
or any aortic regurgitation to be the most accurate of the 
criteria they evaluated for handheld ultrasound. In 
another study that used handheld ultrasound devices in a 
“spiked” cohort (that is, a sample that included known 
cases of RHD), Mirabel and colleagues27 concluded that a 
combination of mitral regurgitation ≥2 cm or any atrial 
regurgitation were the best criteria to use, although a 
shorter mitral regurgitation cut-oﬀ  was noted to be more 
sensitive. The same researchers had previously proposed 
a cut-oﬀ  point of mitral regurgitation ≥2 cm, based on a 
retrospective analysis.28 Ultimately, cut-oﬀ  points for 
screening are always a trade-oﬀ  between sensitivity and 
speciﬁ city, and as such the policy for individual country 
programmes should be based on the tolerance of false-
negative cases and the capacity of the health system.
An important consideration for the feasibility of 
screening programmes is the recall rate: ie, the 
proportion of cases referred for further evaluation due to 
an abnormal screening test, in this case related to the 
prevalence of regurgitation and the test-positive 
predictive value (PPV). In our study, regurgitation was 
detected in 16% (nurse FoCUS) to 25% (standard 
echocardiogram), similar to the 26·5% of high-risk 
children reported from Australia.19 Regurgitation in 
low-risk, healthy populations of children ranges widely 
from 2·5% to 45%, partly due to methodological 
diﬀ erences and the inclusion of closing volumes.29 The 
recall or referral rate and PPV reported in previous 
screening studies has also varied. In Uganda, 2·9% had 
an abnormality on screening, resulting in a PPV of 55%;30 
in Mozambique, 5·7% had suspicious mitral or aortic 
regurgitation, with a PPV of 53%;8 and in New Caledonia, 
8·5% had any abnormality, and a PPV of 11·3%.31 Of 
note, these three studies were done before 2012 and used 
diﬀ erent diagnostic criteria than those used in this study. 
Further, it is possible that children with minor 
abnormalities were detected by the screening 
cardiologists but not referred, which seems to be the case 
in Mozambique, where a subsequent analysis of the 
same data reported that 9·6% had mitral regurgitation, 
resulting in a PPV of 7·2%, which is similar to the 
ﬁ ndings from our study.28
Extrapolation of our results to a population level 
suggests that 1642 of every 10 000 children screened 
would be referred for diagnostic assessment, of whom 
239 would receive a diagnosis of RHD (approximately 
25% deﬁ nite and 75% borderline) and 44 would have 
their diagnosis missed. A recall rate of 16% is not 
excessive for a disease prevalence of 2·8%, and does not 
diﬀ er greatly from the 12% recall rate for ﬁ rst time 
mammography.32 However, to assess the recalled group 
would require a large number of skilled workers, which 
would not be feasible in many settings. To our knowledge, 
New Caledonia,31 Tonga,33 and Samoa34 are the only 
countries to have implemented public-health screening 
programmes for RHD using echocardiography. All have 
populations of less than 300 000 people and the most 
populous of these, New Caledonia, has a substantially 
greater physician workforce capacity than do most 
settings with a high prevalence of RHD.35
Further innovation in RHD screening may result in 
greater accuracy, reduced resource requirements, or both. 
Screening with handheld ultrasonography is one such 
innovation, and is highly accurate when used by 
experienced cardiologists.36-38 Two recent studies have 
assessed non-expert operators.26,27 Although the methods 
varied from our study, the accuracy results were, likewise, 
encouraging. Mirabel and colleagues27 reported 77–84% 
sensitivity and 91–92% speciﬁ city for two nurses in New 
Caledonia, and Ploutz and colleagues26 reported 74% 
sensitivity and 79% speciﬁ city for two nurses with some 
echocardiography experience in Uganda. Compared with 
standard portable machines, handheld machines are less 
expensive and more portable; however, current models 
have short battery life, limited Doppler capabilities, are 
prone to overheating,26,37 and the recall rate of handheld 
screening may be higher (24% in Uganda)26
Although we have used regurgitation as a risk marker 
for disease, this approach has inherent limitations. For 
example, diﬀ erentiation of closing volumes and benign 
mitral regurgitation from true disease, without additional 
valve morphology criteria remains a challenge to the 
accuracy of RHD screening. We tried to exclude closing 
volumes by asking nurses to ignore regurgitation seen in 
only a single frame; however, some closing volumes were 
likely still coded as regurgitation. Speciﬁ city might be 
improved by adopting a more subjective approach, in 
which operators do not refer jets with a benign 
appearance. Screening for regurgitation will also miss 
some cases of congenital heart disease and mitral 
stenosis, which could be important in areas with high 
prevalence of juvenile mitral stenosis. From our 
experience, identiﬁ cation of these lesions or the 
morphological changes of RHD require advanced skills 
that cannot be expected of brieﬂ y trained operators, but 
further investigation is warranted.
Our study has some limitations. Despite our intentions, 
many children did not undergo both tests on the same 
day. However, we believe the interval between tests was 
not clinically relevant and did not aﬀ ect the results. The 
absence of a true gold standard for RHD diagnosis is a 
limitation for comparisons of accuracy. The WHF criteria 
represent important progress; however, some challenges 
remain in the diﬀ erentiation of mild disease from the 
upper limits of normal. For practical reasons and cost, 
one cardiologist reported most of the studies. Our results 
are representative of our study population, our training 
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and screening methods, the ultrasound equipment used, 
and the participating nurses, and, therefore, might not 
be generalisable to other settings. However, these 
limitations are balanced by our rigorous methods, 
consistent with the STARD guidelines,16 a well-deﬁ ned 
training programme,17 and a group of non-expert 
operators trained for RHD screening that was larger than 
that in the other studies we reviewed.
There are a number of pertinent issues that aﬀ ect the 
eﬀ ectiveness of screening as a control strategy. A strong 
health system is required to manage detected patients, 
including delivery of secondary prophylaxis. Further, the 
direct costs and opportunity costs of a screening 
programme should not be underestimated, and data 
from this and other screening studies will inform cost-
eﬀ ectiveness models. Finally, the prognosis of borderline 
and subclinical RHD has not been established,39 and, 
therefore, the beneﬁ ts of detecting and treating these 
cases remains unclear. However, there is a pressing need 
to improve global RHD control, and the rigorous 
investigation of early case detection, including practical 
screening methodologies, should take place in parallel 
with these other evaluations.
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